biotechnolog industri appear pois rapid growth
move second decad shown
deliv marvel drug captiv wall street
estim industri revenu jump sevenfold
$ 40 billion end decad support
bush administr last month propos $ 4
billion program boost biotechnolog research
biotechnolog prove 80s say john
wilkerson new york health-car industri consult
90s go test ground individu
compani
mani new biotech compani alreadi test
stock market unusu compani lose
gain chunk market valu one day wednesday
centocor inc. plung $ 8.125 $ 33.125 question
food drug administr septic shock
drug yet jan. 13 enzo biochem inc. share jump 77 %
compani introduc eight new cancer diagnost
product
far biotechnolog compani amgen
inc. made money inde industri gush
red ink ever year end june 30 loss swell
45 % $ 2.9 billion year earlier accord ernst
young account firm
loss underscor fact great major
industri player still high-risk
development-stag compani could easili scrambl
new nest egg lot young compani sudden got
plenti money say jean deleag san francisco ventur
capitalist demonstr
disciplin spend wise
scienc behind busi advanc fast
research develop cost threaten absorb much
money industri rais surviv compani
focus develop effort much
past even busi find season manag plot
strategi see product market may find
pinch competit also
govern insur industri effort hold
health-car cost
younger compani show
technolog work success turn
effect product say dr. wilkerson consult
matur busi challeng includ
fund enorm expens clinic trial build
manufactur sale oper jockey
talent manag patent corpor partner regulatori
approv ever capit
inordin easier decad ago pick
centocor amgen world emerg
industri leader say peter drake analyst vector
secur intern compani simpler
technolog easier understand competit
much easier assess
industri scientif explos complic
pictur bioengin drug alreadi use treat
anemia immune-system suppress induc anti-canc
drug dwarfism children hepat heart attack
host product test clinic
includ drug kill cancer cell without hurt normal
one prevent blood clot caus stroke
heart attack lab crop plant genet
engin resist pest drug block genet
malfunct under cancer bioengin microb
consum toxic wast medicin arrest disord
age alzheim diseas
100 biotechnolog drug clinic trial
mani compet share market
10 categori novel drug develop treat
autoimmun disord rheumatoid arthriti
multipl sclerosi say david stone analyst cowen
co
one key navig flood product
compani focus say vector mr. drake amgen
success add stem larg mid-1980 decis
compani founder former chairman georg rathmann
look amgen pipelin product cash
said ` ca stuff direct entir
compani focus epo compani lucrat anti-anemia
drug stand alon nich
industri earli day main strategi go
scienc hope get first
add stephen duzan chief execut founder immunex
corp. biotechnolog compani base seattl
busi must select place smaller number
bet care analyz patent posit market
potenti involv drug therapeut valu
also like feder govern health
insur pay
industri whose product cost $ 100 million
develop compani focus earli quick get
overextend consid neorx corp. seattl compani start
1984 develop antibody-bas diagnost anti-canc
agent request feder market approv two
diagnost product four cancer therapeut
diagnost agent clinic trial yet sell
product loss mount steadili total
$ 54 million first six year
cash crunch loom neorx last two year
drastic narrow research develop
activ limit product develop imag
anti-canc area also decid licens first
product outsid compani rather develop
in-hous result reduct work forc
40 % drop burn rate fast compani
use cash third $ 10 million
$ 11 million
anoth lesson biotechnolog first decad
import instal hardhead execut earli
compani need hire manag skill
direct full-servic drug compani research
boutiqu say dr. wilkerson consult
perhap two-third biotechnolog compani tri
recruit senior execut busi develop
profession say mr. deleag ventur capitalist
walter chan cw ventur new york ventur capit
firm add key ingredi increas becom
star manag star molecul
even crack manag team guarante
biotechnolog compani well-laid plan wo go astray
industri biggest uncertainti stem battl
cut health-car cost govern decis whether
pay cost new drug patient cover medicar
program critic drug success
genet engin drug tend cost common
sever thousand dollar cours treatment
becom lightn rod critic seek
hold cost five eight year
look differ cost reimburs
environ drug say linda miller analyst
painewebb inc
inde fear tighten reimburs rule
drug alreadi compani shi away diseas
area consid non-life-threaten immunex pull
back certain woundheal area though
signific market compani help speed wound
heal expens develop drug price
consid reason make
harder recov cost drug treat fatal
diseas say mr. duzan
reimburs polici front
biotechnolog compani feel heat rocket
health-car cost bill recent introduc congress
would cap sale drug feder orphan drug act
law allow compani develop drug diseas
afflict fewer 200,000 peopl grant exclus
market right drug seven year propos
cap would revok exclus cumul sale
orphan drug exceed $ 200 million
bill enact would undercut abil
biotechnolog compani financ drug develop say
henri termeer chief execut genzym corp.
biotechnolog concern cambridg mass. develop
treatment cystic fibrosi orphan drug status
particular mr. termeer argu bill would curtail
use off-balance-sheet financ drug
increas popular strategi compani form
public trade research subsidiari develop drug
mani investor buy share spinoff part
risk balanc potenti larg payoff
product orphan drug status say
mr. termeer argument highlight biotechnolog
expand need capit push product
cost clinic trial phase mani biotechnolog compani
seek partnership goal
becom big independ drug compani past
compani often littl choic trade technolog
money licens pact drug-compani partner
industri basic technolog valid
success launch blockbust drug last year
stock-sel bonanza also strengthen hand
three-year-old isi pharmaceut inc. rais
$ 72 million last year fund mean flexibl
say deal say founder
stanley crook isi continu flog
technolog present potenti partner
process time-consum compani scientist
mr. crook add luxuri hold
find alli bring money competit
advantag compani
true collabor rather trade technolog
money rise biotechnolog compani
bigger partner immulog pharmaceut
corp. cambridg mass. recent agre develop
anti-allergi technolog marion merrel dow inc.
kansa citi mo. drug concern compani form
committe manag side overse work
immulog also retain u.s. right market product base
research
secret success collabor make sure
champion larger compani believ
product say ramesh ratan senior vice presid
repligen corp. cambridg mass. biotechnolog concern
partnership work consid buy
technolog back larger compani project
die vine
last year repligen reacquir right merck co.
certain monoclon antibodi fight aid infect
merck repligen want pursu differ use
technolog mr. ratan say moreov merck licens
similar antibodi anoth biotechnolog concern
medimmun inc. indic larger compani interest
repligen antibodi fallen
partnership biotech drug compani sometim
unravel clash big-compani
small-compani oper style less problem
grow variat partnership theme
collabor biotechnolog compani last year
partnership account half u.
pharmaceut research allianc accord ernst
young
mani biotechnolog compani financi
wherewith play role deep-pocket partner note
richard f. pop presid chief execut offic
alkerm inc. cambridg mass. compani develop
treatment brain diseas rais $ 60
million public offer compani recent agre
fund $ 26.5 million joint research cortex
pharmaceut inc. irvin calif. drug treat
stroke brain disord
relat trend buyer troubl biotechnolog
compani increas like biotech
concern note exampl chiron corp. purchas
cetus corp. last year stock swap valu $ 660 million
trend help prevent slow biotechnolog
financi momentum say vector secur mr. drake even
stock market generous industri
next year 1991 good news
biotech industri self-rejuven
move 1990s say

biotech world


lead biotechnolog compani rank stock
market capit


stock proprietari
market number drugs* drug
capital- pre- await human
izat clinic clinic fda
$ million trial trial approv market


amgen



genentech
3,080.2 n.a 10 0 3


chiron
1,509.6 7 14 0 3


centocor
1,296.8 0 5 3 0


synergen
1,205.4 6 3 0 0


genzym
935.9 1 1 0 1


biogen
879.8 3 3 0 2


gensia
860.1 8 1 0 0


immunex
791.8 4 4 1 2


allianc
644.0 7 2 1 0


us bioscienc
570.8 4 4 1 1


xoma
489.5 7 6 2 0


medimmun
448.8 6 1 0 1


affymax
409.6 0 0 0 0


immun respons
395.2 1 1 0 0


genet institut
379.6 3 3 2 1


molecular biosystem
373.8 0 0 1 0


cytogen**
352.3 0 1 0 0


immunomed
337.1 1 2 0 0


liposom co



*number indic actual number compound
develop therapeut purpos
compani may develop singl compound sever
indic
**primari interest nondrug medic product


n.a.=not avail


sourc wilkerson group new york
